Hydrogen Gas / NRF2 Cancer Research Results

H2, Hydrogen Gas: Click to Expand ⟱
Features:
Hydrogen Gas, Powerful Antioxidant
Mechanistically, H₂ is most defensibly framed as a selective antioxidant + anti-inflammatory signaling modulator (often via Nrf2↑ and NF-κB↓ / NLRP3↓), with strongest clinical relevance in oncology being reduction of treatment toxicities (radiation/CCRT side-effects), with mixed/early evidence for direct anticancer effects.

1.Antioxidant and Nrf2/ARE Pathway: activate Nrf2, which induces antioxidant enzymes.
2.NF-κB Pathway: reported to inhibit NF-κB activation, thereby reducing inflammatory cytokine production
3.Mitochondrial Apoptosis Pathway
4.MAPK (Mitogen-Activated Protein Kinases) Pathway
5.PI3K/Akt/mTOR Pathway
6.Inflammatory Cytokine Signaling: Reducing cytokines (such as IL-6, TNF-α)
7.p53 Pathway
8.Autophagy Pathways: might regulate autophagy, (dual roles in cancer)

Example unit sometimes used in studies
Example Canadian Supplier

Hydrogen gas can be generated in small amount by hydrogenase of certain members of the human gastrointestinal tract microbiota from unabsorbed carbohydrates in the intestine through degradation and metabolism, which then is partially diffused into blood flow and released and detected in exhaled breath, indicating its potential to serve as a biomarker.

Many studies have shown that H2 therapy can reduce oxidative stress. This, however, contradicts radiation therapy and chemotherapy, in which ROS are required to induce apoptosis and combat cancer. Yet many studies show chemoprotective and radioprotective and some even show chemosentizing
Nevertheless there are some papers claiming ROS ↑ for cancer cells

Hydrogen Gas in Water is also used.
- the amount of H2 dissolved in solutions is limited: up to 0.8 mM (1.6 mg/L) H2 can be dissolved in water under atmospheric pressure at room temperature

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Selective ROS/RNS buffering (•OH, ONOO− emphasis) Oxidative damage tone ↓ (context-dependent) Radiation/chemo oxidative injury ↓ P, R Rapid cytoprotection Landmark work proposes H2 selectively reduces highly reactive species (e.g., hydroxyl radical) rather than globally suppressing signaling ROS. Treat as "selective antioxidant" rather than broad ROS quencher.
2 Nrf2 antioxidant response (Keap1/Nrf2; SOD/GPx/GSH systems) Stress adaptation modulation (context-dependent) Nrf2 ↑; endogenous antioxidant enzymes ↑ R, G Endogenous antioxidant upshift Multiple reviews describe H2 as engaging Nrf2-linked programs and increasing antioxidant enzyme activity; direction in tumors is model-specific and should not be oversold as uniformly anti-tumor.
3 NF-κB inflammatory transcription Inflammatory/pro-survival transcription ↓ (context) Inflammation ↓ (tissue protective) R, G Anti-inflammatory signaling Commonly reported downstream of redox modulation: reduced NF-κB activity and reduced inflammatory cytokine outputs.
4 NLRP3 inflammasome (priming/activation) Inflammasome signaling ↓ (context) NLRP3 activation ↓; tissue injury signaling ↓ R, G Inflammasome dampening Often described as part of an antioxidant–anti-inflammatory synergy (Nrf2↑ with NF-κB/NLRP3↓). Use "reported" language.
5 Mitochondrial protection / mitochondrial ROS Mito-stress tone ↓ (context) Mitochondrial function preserved; oxidative injury ↓ R, G Bioenergetic stabilization Frequently reported as reduced mitochondrial oxidative injury and improved cellular resilience in injury/inflammation models.
6 Radiation/CCRT toxicity mitigation (clinical relevance) Adjunct use: may reduce acute radiation toxicities without obvious loss of tumor control (early evidence) Mucositis/dermatitis/inflammation severity ↓ (reported) G Supportive care Clinical studies report feasibility/safety and reduced radiotherapy-related toxicities in selected settings; treat as supportive/adjunct, not standalone anti-cancer therapy.
7 Apoptosis / proliferation control Mixed reports: apoptosis ↑ or neutral depending on model Often anti-apoptotic in injury models G Context-dependent cell fate shift Unlike classic cytotoxins, H2 effects on apoptosis/proliferation are not uniform; keep as model-dependent and secondary.
8 Clinical safety signal (inhalation studies) Generally well tolerated at low concentrations in studied settings Translation constraint / safety framing Human safety studies exist for low-concentration inhalation; practical use must be medical-grade and safety-controlled due to flammability risk.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (direct chemical/rapid signaling effects)
  • R: 30 min–3 hr (acute redox + inflammatory signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)


NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
3767- H2,    The role of hydrogen therapy in Alzheimer's disease management: Insights into mechanisms, administration routes, and future challenges
- Review, AD, NA
*Inflam↓, *neuroP↑, *toxicity↓, *antiOx↑, *ROS↓, *NLRP3↓, *IL1β↓, *mtDam↓, *ATP↑, *AMPK↑, *FOXO3↑, *SOD1↑, *Catalase↑, *NRF2↑, *NO↓, *MDA↓, *lipid-P↓, *memory↑, *ER(estro)↓, *BDNF↑, *cognitive↑, *APP↓, *BACE↓, *Aβ↓, *BP∅, *BBB↑,
3770- H2,    Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases
- Review, AD, NA - Review, Park, NA
*antiOx↑, *NRF2↑, *HO-1↑, *Inflam↓, *neuroP↑, *cardioP↑, *other↓, *ROS↓, *NADPH↓, *Catalase↑, *GPx1↑, *NO↓, *mt-ROS↓, *SIRT3↑, *SIRT1↑, *TLR4↓, *mTOR↓, *cognitive↑, *Sepsis↓, *PTEN↓, *Akt↓, *NLRP3↓, *AntiAg↑, *IL6↓, *TNF-α↓, *IL1β↓, *MDA↓, *memory↑, *FOXO3↑, TumCG↓, *LDL↓,
3773- H2,    Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases
- Review, Park, NA
*neuroP↑, *antiOx↑, *Inflam↓, *ROS↓, *NADPH↓, *NRF2↑, *BBB↑, *IL1β↓, *IL6↓, *TNF-α↓, *NF-kB↓, *NLRP3↓, *Sepsis↓, *p‑mTOR↓, *AMPK↑, *SIRT1↑, *HO-1↑,
3761- H2,    Therapeutic Inhalation of Hydrogen Gas for Alzheimer's Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study
- Human, AD, NA
*cognitive↑, *BBB↑, *ROS↓, *NRF2↑, *Inflam↓, *NFAT↓, *FAO↓, *4-HNE↓, *PGC-1α↑, *Ferroptosis↓,
2508- H2,    Molecular hydrogen is a promising therapeutic agent for pulmonary disease
- Review, Var, NA - Review, Sepsis, NA
*ROS↓, eff↝, *Inflam↓, *NRF2↑, *HO-1↑, *SOD↑, *Catalase↑, *MPO↑, *ASK1↓, *NADPH↓, *Sepsis↓, *HMGB1↓, ROS↑, NLRP3↑, GSDMD↑, chemoP↑, eff↑,
2514- H2,    Hydrogen: A Novel Option in Human Disease Treatment
- Review, NA, NA
*Inflam↓, *IL1β↓, *IL6↓, *IL8↓, *IL10↓, *TNF-α↓, *ROS↓, *HO-1↓, *NRF2↑, *ER Stress↓, H2O2↑,
2516- H2,    Hydrogen Gas in Cancer Treatment
- Review, Var, NA
*Half-Life↓, *ROS↓, *selectivity↑, *SOD↑, *HO-1↑, *NRF2↑, *chemoP↑, *radioP↑, ROS↑, *Inflam↓, eff↑, *TNF-α↓, *IL6↓, *cl‑Casp8↑, *Bax:Bcl2↓, *Apoptosis↓, *cardioP↑, *hepatoP↑, *RenoP↑, *chemoP↑, eff↝, chemoP↑, radioP↑, eff↑, TumCG↓, Ki-67↓, VEGF↓, selectivity↑,
2521- H2,    Oxyhydrogen Gas: A Promising Therapeutic Approach for Lung, Breast and Colorectal Cancer
- Review, CRC, NA - Review, Lung, NA - Review, BC, NA
Inflam↑, ROS↓, ChemoSen↑, p‑PI3K↓, p‑Akt↓, QoL↑, GutMicro↑, chemoP↑, radioP↑, *NRF2↑, *Catalase↑, *GPx↑, *HO-1↑, *SOD↑, *TNF-α↓, *IL4↓, *IL6↓, ChemoSen↑, Appetite↑, cognitive↑, Pain↓, Sleep↑, other?,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

H2O2↑, 1,   ROS↓, 1,   ROS↑, 2,  

Cell Death

p‑Akt↓, 1,   GSDMD↑, 1,  

Transcription & Epigenetics

other?, 1,  

Proliferation, Differentiation & Cell State

p‑PI3K↓, 1,   TumCG↓, 2,  

Migration

Ki-67↓, 1,  

Angiogenesis & Vasculature

VEGF↓, 1,  

Immune & Inflammatory Signaling

Inflam↑, 1,  

Protein Aggregation

NLRP3↑, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 2,   eff↑, 3,   eff↝, 2,   selectivity↑, 1,  

Clinical Biomarkers

GutMicro↑, 1,   Ki-67↓, 1,  

Functional Outcomes

Appetite↑, 1,   chemoP↑, 3,   cognitive↑, 1,   Pain↓, 1,   QoL↑, 1,   radioP↑, 2,   Sleep↑, 1,  
Total Targets: 25

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

4-HNE↓, 1,   antiOx↑, 3,   Catalase↑, 4,   Ferroptosis↓, 1,   GPx↑, 1,   GPx1↑, 1,   HO-1↓, 1,   HO-1↑, 5,   lipid-P↓, 1,   MDA↓, 2,   MPO↑, 1,   NRF2↑, 8,   ROS↓, 7,   mt-ROS↓, 1,   SIRT3↑, 1,   SOD↑, 3,   SOD1↑, 1,  

Mitochondria & Bioenergetics

ATP↑, 1,   mtDam↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis

AMPK↑, 2,   FAO↓, 1,   LDL↓, 1,   NADPH↓, 3,   SIRT1↑, 2,  

Cell Death

Akt↓, 1,   Apoptosis↓, 1,   ASK1↓, 1,   Bax:Bcl2↓, 1,   cl‑Casp8↑, 1,   Ferroptosis↓, 1,  

Transcription & Epigenetics

other↓, 1,  

Protein Folding & ER Stress

ER Stress↓, 1,  

Proliferation, Differentiation & Cell State

FOXO3↑, 2,   mTOR↓, 1,   p‑mTOR↓, 1,   PTEN↓, 1,  

Migration

AntiAg↑, 1,   APP↓, 1,   NFAT↓, 1,  

Angiogenesis & Vasculature

NO↓, 2,  

Barriers & Transport

BBB↑, 3,  

Immune & Inflammatory Signaling

HMGB1↓, 1,   IL10↓, 1,   IL1β↓, 4,   IL4↓, 1,   IL6↓, 5,   IL8↓, 1,   Inflam↓, 7,   NF-kB↓, 1,   TLR4↓, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission

BDNF↑, 1,  

Protein Aggregation

Aβ↓, 1,   BACE↓, 1,   NLRP3↓, 3,  

Hormonal & Nuclear Receptors

ER(estro)↓, 1,  

Drug Metabolism & Resistance

Half-Life↓, 1,   selectivity↑, 1,  

Clinical Biomarkers

BP∅, 1,   IL6↓, 5,  

Functional Outcomes

cardioP↑, 2,   chemoP↑, 2,   cognitive↑, 3,   hepatoP↑, 1,   memory↑, 2,   neuroP↑, 3,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,  

Infection & Microbiome

Sepsis↓, 3,  
Total Targets: 71

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
8 Hydrogen Gas
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:295  Target#:226  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page